Amoeba Sa · EURONEXT:ALMIB
Amoeba Sa — Investor Presentation (October 2024)
18 slides from Amoeba Sa's investor presentation, October 2024
Slide 1: October 2024 | Investors presentation
October 2024 | Investors presentation
Slide 2: Introduction: Your contacts
Introduction YOUR CONTACTS A new dynamic driven by a united team with solid experience in international environments Benoit VILLERS Jean-François DOUCET Chairman of the Board of Directors CEO and Chief Financial Officer Since December 2023 Since May 2023 • 30 years' experience in management and • Me
Slide 3: An experienced management
Finance AN EXPERIENCED MANAGEMENT Board of Directors CODIR Benoit VILLERS Jean-François DOUCET Chairman CEO and CFO Valérie LORENTZ-POINSOT Quentin HUA Jean-Baptiste EBERST CEO Laboratoires Boiron M&A. Laboratoires Boiron 17 years of expertise (2019 – 2024) Director of Regulatory Affairs Patrice SEL
Slide 4: A Lyon-based greentech listed on Euronext Growth
Introduction A LYON-BASED GREENTECH LISTED ON EURONEXT GROWTH Amoéba specializes in the development of natural microbiological solutions based on the patented use of amoebas 2 1 39 1 20 Business focus: Development Patents Production unit in Employees biocontrol and platform Chassieu (France) cosmeti
Slide 5: The amoeba, definition and specific features
Innovation THE AMOEBA, DEFINITION AND SPECIFIC FEATURES An amoeba Our amoeba A naturally occurring unicellular microorganism found in all Origin environmental compartments, particularly in humid W. magna C2C Maky biosourced in Aix-les-Bains thermal spring water, and secure storage environments, incl
Slide 6: A know-how unique in the world
Innovation A KNOW-HOW UNIQUE IN THE WORLD The only company to exploit the amoeba A proven effectiveness of our product Context Biocontrol The industry has focused on pathogenic amoebae, neglecting Efficacy confirmed by the positive conclusions of the rapporteur non-pathogenic amoebae despite their b
Slide 7: A technological platform with multiple applications
Strategy A TECHNOLOGICAL PLATFORM WITH MULTIPLE APPLICATIONS 2 pre-marketing ranges Biocontrol Cosmetics Crop treatment Cosmetics ingredient Natural crop protection method, Skin care and well-aging key alternative to conventional ingredients: thickness and chemical pesticides and one of suppleness o
Slide 8: Axpera
Application - Biocontrol AXPERA ® A real solution for the transition from chemical to organic production Positive impact on agriculture Marketing targeted from 2025 Highly competitive level of performance More than 600 tests carried out in 19 countries Easy to combine with chemical products Active s
Slide 9: The ideal solution to reduce the use of copper
Application - Biocontrol THE IDEAL SOLUTION TO REDUCE THE USE OF COPPER Efficacy on powdery mildew for tomatoes Context Copper is widely used to combat mildew, but its use poses environmental problems. From 2025, European regulations will continue to reduce the use of copper in agriculture. Solution
Slide 10: Skin protection (anti-ageing/anti-UV): in-vitro tests
Application - Cosmetics SKIN PROTECTION (ANTI-AGEING/ ANTI-UV) A recent and promising innovation with proven effects - in-vitro tests October 2023 - Remarkable in vitro studies Anti-ageing effect A restored skin structure Anti-UV effect Young skin irradiated Young skin treated and with UV then irrad
Slide 11: Skin protection (anti-ageing/anti-UV): clinical study
Application - Cosmetics SKIN PROTECTION (ANTI-AGEING/ ANTI-UV) A recent and promising innovation with proven effects – clinical study May 2024 – the clinical study Wrinkle reduction after 28 days confirms excellent in-vitro tests Photo of the Institut d'Expertise Clinique Results of clinical trials
Slide 12: Skin protection: cosmetics commercialization timeline
Application - Cosmetics SKIN PROTECTION (ANTI-AGEING/ ANTI-UV) A recent and promising innovation with proven effects – clinical study March 2024 Registration of our cosmetic ingredient on the INCI (International Nomenclature of Cosmetics Ingredients) product list 2025 Business development agreement(
Slide 13: Scalable industrial capacities
Production SCALABLE INDUSTRIAL CAPACITIES A strategy to minimze direct investment 2024 2025 / 2026 By 2026 Existing line in Chassieu. Capacity increase in 3 phases at Chassieu. Priority given to finding a production Current capacity of 0.5 T Gradual increase from 0.5 T to 10 T of partnership (CDMO)
Slide 14: A profitable company by 2027, with a committed core shareholder
Trajectory A PROFITABLE COMPANY BY 2027, WITH A COMMITTED CORE SHAREHOLDER 2023 by 2027 Perfectly controlled financing requirements €12m Revenues • Secure financing of operations by the reference shareholder in 2024 • Pre-commercialisation calibrated to minimise WCR for the €0m Break even start of s
Slide 15: A legal reorganisation project
Organisation A LEGAL REORGANISATION PROJECT Listed company • R&D AMOÉBA S.A. • Production • Support services Operating companies Cosmetics Biocontrol • By activity 30.10.2024 15
Slide 16: Investing in Amoeba
Conclusion INVESTING IN AMOEBA Why today ? Biocontrol The solution for reducing the use of chemicals and copper in agriculture, for which approval is imminent Cosmetics Scientific and clinically proven results for anti-ageing effects that open up a new area of development Development platform Other
Slide 17: Amoéba amoeba-nature.com amoeba@actus.fr
Amoéba amoeba-nature.com amoeba@actus.fr
Slide 18: Disclaimer
DISCLAIMER References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question-and-answer session following that oral presentation and any further information that may b